ABBV-CLS-628

ABBV-CLS-628 is an investigational monoclonal antibody therapeutic developed through a collaboration between AbbVie and Calico Life Sciences. It is being studied primarily for the treatment of autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder characterized by the development of fluid-filled cysts in the kidneys that can lead to kidney failure[1][3][4]. While its precise mechanism of action has not been officially disclosed in public databases, preclinical research and patent filings suggest that ABBV-CLS-628 acts as an inhibitor of Pregnancy-Associated Plasma Protein A (PAPP-A), a proteinase involved in regulating local bioavailability of Insulin-like Growth Factor 1 (IGF-1)[4][7]. Inhibition of PAPP-A has shown significant benefits in animal models, including reduced renal cyst burden, decreased inflammation and fibrosis, improved kidney function, and extended lifespan[4][7]. The drug is administered intravenously and is currently advancing from preclinical to Phase 2 clinical trials for ADPKD[1][2][3][5].

Other names

pappa neutralizing monoclonal antibodyPregnancy-associated plasma protein-A neutralizing monoclonal antibodyPAPP-A neutralizing mAb